↓ Skip to main content

Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives

Overview of attention for article published in Frontiers in endocrinology, January 2014
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
63 Dimensions

Readers on

mendeley
60 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives
Published in
Frontiers in endocrinology, January 2014
DOI 10.3389/fendo.2014.00007
Pubmed ID
Authors

Roberto Baldelli, A. Barnabei, L. Rizza, A. M. Isidori, F. Rota, P. Di Giacinto, A. Paoloni, F. Torino, S. M. Corsello, A. Lenzi, M. Appetecchia

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that present many clinical features secreting peptides and neuroamines that cause distinct clinical syndromes such as carcinoid syndrome. However most of them are clinically silent until late presentation with mass effects. Surgical resection is the first line treatment for a patient with a GEP-NET while in metastatic disease multiple therapeutic approaches are possible. GEP-NETs are able to express somatostatin receptors (SSTRs) bounded by somatostatin (SST) or its synthetic analogs, although the subtypes and number of SSTRs expressed are very variable. In particular, SST analogs are used frequently to control hormone-related symptoms while their anti-neoplastic activity seems to result prevalently in tumor stabilization. Patients who fail to respond or cease to respond to standard SST analogs treatment seem to have a response to higher doses of these drugs. For this reason, the use of higher doses of SST analogs will probably improve the clinical management of these patients.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Mexico 1 2%
Brazil 1 2%
Unknown 57 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 9 15%
Student > Bachelor 8 13%
Researcher 7 12%
Other 6 10%
Student > Doctoral Student 4 7%
Other 11 18%
Unknown 15 25%
Readers by discipline Count As %
Medicine and Dentistry 24 40%
Agricultural and Biological Sciences 7 12%
Biochemistry, Genetics and Molecular Biology 4 7%
Chemistry 3 5%
Nursing and Health Professions 2 3%
Other 4 7%
Unknown 16 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2014.
All research outputs
#20,712,696
of 26,311,549 outputs
Outputs from Frontiers in endocrinology
#6,076
of 13,417 outputs
Outputs of similar age
#239,074
of 322,969 outputs
Outputs of similar age from Frontiers in endocrinology
#18
of 27 outputs
Altmetric has tracked 26,311,549 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 13,417 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,969 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.